Single answer
Is Apollomics Inc (APLM) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
No analyst target data available for this ticker.
Company snapshot
A quick overview of the business and its public profile.
Apollomics Inc a biotechnology company engages in the discovery and development of oncology therapies to address unmet medical needs in California Hangzhou Shanghai China and Australia It develops APL101 Vebreltinib a potent selective cMet inhibitor for the treatment of nonsmall cell lung cancer and other advanced tumors APL102 is an oral active small molecule multiple tyrosine kinase inhibitor for liver cancer breast cancer and esophageal cancer and APL122 a tumor inhibitor candidate to treat cancers within the brain The company was formerly known as CBT Pharmaceuticals Inc and changed its name to Apollomics Inc in January 2019 Apollomics Inc was incorporated in 2015 and is based in Foster City California
Website: https://www.apollomicsinc.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.07. Cash flow to debt ratio: -38.63. Net profit margin: -450.04%. Inflation risk score: medium (0.70/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
No, the average daily trading liquidity for Apollomics Inc is $816,674. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
10-year return check
We cannot find data for Apollomics Inc 10 years ago, but if you had invested on 2021-11-26 when the price was $9.90, you would have made a profit of $10.78 per share or 108.89%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.
No analyst target data available for this ticker.